Improved oral drug delivery: Solubility limitations overcome by the use of prodrugs

Advanced Drug Delivery Reviews

Volumn 19, Issue 2, 1996, Pages 115-130

  Fleisher, David ^a   Bong, Ramon ^a   Stewart, Barbra H ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b PFIZER INC   (United States)

Author keywords

Dissolution; Intestinal absorption; Oral absorption; Prodrug formulation; Prodrug oral bioavailability; Soluble prodrug

Indexed keywords

ABSORPTION; AMINES; DISSOLUTION; DRUG INTERACTIONS; DRUG PRODUCTS; ESTERIFICATION; HYDROLYSIS; MOLECULAR DYNAMICS; SOLUBILITY;

CHEMICAL DERIVATIZATION; DRUG SOLUBILIZATION; INTERMOLECULAR INTERACTIONS; INTESTINAL ABSORPTION; MEMBRANE CARRIER TARGETING; ORAL ABSORPTION; ORAL DRUG DELIVERY; PRODRUG FORMULATION; PRODRUG ORAL BIOAVAILABILITY; PRODRUGS;

DRUG THERAPY;

ACICLOVIR; ALBENDAZOLE; BETA LACTAM ANTIBIOTIC; BI L 357; CARRIER PROTEIN; CEFCANEL DALOXATE; CROMOGLYCATE DISODIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETOPOFOS; ETOPOSIDE; FOSPHENYTOIN SODIUM; HYDROCORTISONE; MEBENDAZOLE; MK 0287; PACLITAXEL; PHENYTOIN; PRAZOSIN; PRODRUG; UNCLASSIFIED DRUG;

DERIVATIZATION; DISSOLUTION; DRUG ABSORPTION; DRUG ANALYSIS; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG FORMULATION; DRUG HYDROLYSIS; DRUG SOLUBILITY; ESTERIFICATION; INTESTINE ABSORPTION; MEMBRANE PERMEABILITY; MEMBRANE TRANSPORT; PHARMACEUTICS; PRIORITY JOURNAL; REVIEW;

EID: 0342832999     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-409X(95)00103-E     Document Type: Review

References (51)

1. Yalkowsky, S.H. (1981) Techniques of Solubilization of Drugs, Marcel Dekker, New York.
2. Anderson, B.D. (1985) Prodrugs for improved formulation properties. In: H. Bundgaard (Ed.), Design of Prodrugs, Elsevier, Amsterdam, pp. 243-270.
3. Stella, V. (1974) Prodrugs: An overview and definition. In: T. Higuchi and V. Stella (Eds.), Prodrugs as Novel Drug Delivery Systems, ACS Symposium Series, pp. 1-115.
4. Amidon, G.L. (1981) Drug derivatization as a means of solubilization: Physicochemical and biochemical strategies. In: S.H. Yalkowsky (Ed.), Techniques of Solubilization of Drugs, Marcel Dekker, New York, pp. 183-211.
5. Takata, J., Karube, Y., Nagata, Y. and Matsushima, Y. (1995) Prodrugs of vitamin E: preparation and enzymatic hydrolysis of aminoalkanecarboxylic acid esters of d-α-tocopherol. J. Pharm. Sci. 84, 96-98.
6. Fleisher, D., Johnson, K.C., Stewart, B.H. and Amidon, G.L. (1986) Oral absorption of 21-corticosteroid esters: a function of aqueous stability and intestinal enzyme activity and distribution. J. Pharm, Sci. 75, 934-939.
7. Amidon, G.L., Leesman, G.D. and Elliott, R.L. (1980) Improving intestinal absorption of water-insouble compounds: a membrane metabolism strategy. J. Pharm. Sci., 69, 1363-1368.
8. Mizuma, T., Ohta, K., Hayashi, M. and Awazu, S. (1992) Intestinal active absorption of sugar-conjugated compounds by glucose transport system: implication of improvement of poorly absorbable drugs, Biochem. Pharmacol. 43, 2037-2039,
9. Ho, N.F.H. (1987) Utilizing bile acid carrier mechanisms to enhance liver and small intestine absorption. Ann. N.Y. Acad. Sci. 507, 315-329.
10. Safadi, M., Oliyai, R. and Stella, V.J. (1993) Phosphoryloxymethyl carbamates and carbonates - novel water-soluble prodrugs for amines and hindered alcohols. Pharm. Res. 10, 1350-1355.
11. Nielsen, L.S., Slok, F. and Bundgard, H. (1994) N-Alkoxycarbonyl prodrugs of mebendazole with increased water solubility. Int. J. Pharm. 102, 231-239.
12. Sakamoto, F., Ikeda, S. and Tsukamoto, G. (1984) Studies on prodrugs: preparation and characterization of 5-substituted (2-oxo-1,3-dioxolen-4-yl)methyl esters of ampicillin. Chem. Pharm. Bull. 32, 2241-2248.
13. Kakeya, N., Nishizawa, S., Nishimura, K.I., Yoshimi, A., Tamaki, S., Mori, T. and Kitao, K. (1985) KY-109, a new bifunctional prodrug of a cephalosporin. J. Antibiot. 38, 380-389.
14. Beauchamp, L.M., Orr, G.F., DeMiranda, P., Burnette, T. and Krenitsky, T.A. (1992) Amino acid ester prodrugs of acyclovir. Antivir. Chem. Chemother. 3, 157-164.
15. DeMiranda, P. and Burnette, T. (1994) Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys. Drug Metab. Dispos. 22, 55-58.
16. Bentley, S., Soul-Lawton, J. and Rolan, P. (1994) Absolute bioavailability of acyclovir is substantially increased following oral valaciclovir. Int. Conf. AIDS 10, 127.
17. Hodge, R.A.V., Sutton, D., Boyd, M.R., Harnden, M.R. and Jarvest, R.L. (1989) Selection of an oral prodrug, famciclovir, for the antiherpes virus agent, penciclovir. Antimicrob. Agents Chemother. 33, 1765-1773.
18. Cundy, K.C., Fishback, J.A., Shaw, J.P., Lee, M.L., Soike, K.F., Visoe, G.C. and Lee, W.A. (1994) Oral bioavailability of antiretroviral agent 9-(2-phosphonylmethoxyethyl) adenine (PMEA) from three formulations of the prodrug bis(pivaloyloxymethyl)-PMEA in fasted male cynomolgus monkeys. Pharm. Res. 11, 839-843.
19. Hasegawa, T., Seki, T., Juni, D., Saneyoshi, M. and Kawaguchi, T. (1993) Prodrugs of 2″,3″-didehydro-3-deoxythymidine. J. Pharm. Sci. 82, 1232-1236.
20. Buur. A. and Bundgaard, H. (1987) Prodrugs of 5-fluorouracil: improved rectal and oral delivery of 5-fluorouracil via various prodrugs. Int. J. Pharm. 36, 41-49.
21. Donnegan, S. (1989) An unusual reaction to etoposide. Ann. Pharmacother. 23, 177.
22. Clark, P.I. and Slevin, M.L. (1987) The clinical pharmacology of etoposide and teniposide. Clin. Pharmacokinet. 12, 223-252.
23. Shah, J.C., Chen, J.R. and Chow, D. (1992) Oral bioavailability and in situ absorption of etoposide in the rat. Int. J. Pharm. 84, 223-232
24. Shah, J.C., Chen, J.R. and Chow, D. (1989) Preformulation study of etoposide: identification of physical chemical characteristics responsible for the low and erratic oral bioavailability of etoposide. Pharm. Res. 6, 408-413.
25. Doyle, T.W. and Vyas, D.M. (1990) Second generation analogs of etoposide and mitomycin C. Cancer Treat. Rev. 17, 127-131.
26. Carney, D.N. (1990) The pharmacology of intravenous and oral etoposide. Cancer 67, 299-302.
27. Sessa, C., Zucchetti, M., Cerny, T., Pagani, O., DeFusco, M., DeJong, J., Gentili, D., McDaniel, C., Prins, C., Schacter, L., Winograd, B. and D'Incalci, M. (1995) Phase I clinical and pharmacokinetic study of oral etoposide phosphate. J. Clin. Oncol. 13, 200-209.
28. Rowinsky, E.K., Casenave, L.A. and Donehower, R.C. (1990) Taxol - a novel investigational antimicrotubule agent. J. Natl. Cancer Inst. 82, 1247-1259.
29. Vyas, D.M., Wong, H., Crosswell, A.R., Casazza, A.M., Knipe, J.O., Mamber, S.W. and Doyle, T.W. (1993) Synthesis and antitumor evaluation of water-soluble taxol phosphates. Bioorg. Med. Chem. Lett. 3, 1357-1360.
30. Ueda, Y., Mikkilineni, A.B., Knipe, J.O., Rose, W.C., Casazza, A.M. and Vyas, D.M. (1993) Novel water-soluble phosphate prodrugs of taxol possessing in vivo antitumor activity. Bioorg. Med. Chem. Lett. 3, 1761-1766.
31. Wiernik, P.H., Schwartz, E.L., Einzig, A., Strauman, J.J., Lipton, R.B. and Dutcher, J.P. (1987) Phase I trial of taxol given as a 24-hour infusion every 21 days -responses observed in metastatic melanoma. J. Clin. Oncol. 5, 1232-1239.
32. Varia, S.A., Schuller, S. and Stella, V.J. (1984) Phentoin prodrugs IV: Hydrolysis of various 3-(hydroxy-methyl)phenytoin esters. J. Pharm. Sci. 73, 1074-1080.
33. Varia, S.A., Schuller, S., Sloan, K.B. and Stella, V.J. (1984) Phenytoin prodrugs III: Water-soluble prodrugs for oral and/or parenteral use. J. Pharm. Sci 73, 1068-1073.
34. Fleisher, D., Sheth, N., Griffin, H., McFadden, M. and Aspacher. G. (1989) Nutrient influences on rat intestinal phenytoin uptake. Pharm. Res. 6, 332-337.
35. TenHoor, C.N. and Stewart, B.H. (1995) Reconversion of fosphenytoin in the presence of intestinal alkaline phosphatase. Pharm. Res. 12, 1806-1809.
36. Varia, S.A. and Stella, V.J. (1984) Phenytoin prodrugs V: In vivo evaluation of some water-soluble phenytoin prodrugs in dogs. J. Pharm. Sci. 73, 1080-1084.
37. Pochopin, N.L., Charman, W.N. and Stella, V.J. (1994) Kinetics of rearrangement and hydrolysis of amino acid derivatives of prazosin. Int. J. Pharm. 105, 169-176.
38. Patt, W.C., Hamilton, H.W., Ryan, M.J., Painchaud, C.A., Taylor, M.D., Rapundalo, S.T., Batley, B.L., Connolly, C.J.C. and Taylor, D.G. (1992) A novel orally active renin inhibitor containing 2-amino-4-thiazolyl-alanine at P2 with a long duration of action in a primate model of hypertension. Med. Chem. Res. 2, 10-15.
39. Wright J.L., Kugler, A.R., Stewart, B.H. and Taylor, M.D. (1992) Amino acid esters as prodrugs of renin inhibitor. American Chemical Society, Division of Medicinal Chemistry, Abstract No. 57, Washington, DC.
40. Stewart, B.H., Massey, K.D., Kugler, A.R., Wright, J.L., Repine, J.T. and Taylor, M.D. (1992) Amino acid esters as renin inhibitor prodrugs: stability to hydrolysis by pancreatic enzymes and selectivity for reconversion by intestinal brush border membrane aminopeptidases. Pharm. Res. 9, S-177.
41. Cheng, X.M., Taylor, M.D., Stewart, B.H., Massey, K.D., Kugler, A.R., Rapundalo, S.R., Hingorani, G. and Hurley, T. (1993) P4 attachment of amino acid esters as prodrugs of renin inhibitors. American Chemical Society, Division of Medicinal Chemistry, Abstract No. 55, Chicago, IL.
42. Amidon, G.L., Sinko, P.J. and Fleisher D. (1988) Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm. Res. 5, 651-654.
43. Yoshimi, A., Hashizume, H., Tamaki, S., Tsuda, H., Fukata, D., Nishimura, K. and Yata, N. (1992) Importance of hydrolysis of amino acid moiety in water-soluble prodrugs of disodium cromoglycate for increased oral bioavailability. J. Pharmacobio-Dyn. 15, 339-345.
44. Yoshimi, A., Hashizume, H., Kitagawa, M., Nishimura, K. and Kakeya, N. (1992) Characteristics of 1,3-bis-(2-ethoxycarbonylchromon-5-yloxy)-2-(S)-lysyloxy)propane dihydrochloride (N-556), a prodrug for the oral delivery of disodium cromoglycate, in absorption and excretion in rats and rabbits. J. Pharmcobio-Dyn. 15, 681-686.
45. Farina, P.R., Graham, A.G., Homon, C.A., Lazer, E.S., Hattox, S.E., Riska, P.S., Gundel, R.H. and Wegner, C.D. (1993) A prodrug of a 2,6-disubstituted 4-(2-arylethenyl)phenol is a selective and orally active 5-lipoxygenase inhibitor. J. Pharmacol. Exp. Ther. 265, 483-488.
46. Girotra, N.N., Biftu, T., Ponpipom, M.M., Acton, J.J., Alberts, A.W., Bach, T.N., Ball, R.G., Bugianesi, R.L., Parsons. W.H., Chabala, J.C., Davies, P., Doebber, T.W., Doherty, J., Graham, D.W., Hwang, S.B., Kuo, C.H., Lam, M.H., Luell, S., MacIntyre, D.E., Meurer, R., Roberts, C.D., Sahoo, S.P. and Wu, M.S. (1992) Development, synthesis and biological evaluation of (-)-trans-(25,5S)-2-[3-[(2-oxopropyl)sulfonyl]-4-n-propoxy-5-(3-hydroxypropoxy) phenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran, a potent orally active platelet-activating factor (PAF) antagonist and its water-soluble prodrug phosphate ester. J. Med. Chem. 35, 3474-3482.
47. DeCapprariis, P., Palagiano, F., Bonina, F., Montenegro, L., D'Amico, M. and Rossi, F. (1994) Synthesis and pharmacological evaluation of oligoethylene ester derivatives as indomethacin oral prodrugs. J. Pharm. Sci. 83, 1578-1581.
48. Shanbhag, V.R., Crider, M., Gokhale, R., Harpalani, A. and Dick, R.M. (1992) Ester and amide prodrugs of ibuprofen and naproxen: synthesis, anti-inflammatory activity, and gastrointestinal toxicity. J. Pharm. Sci. 81, 149-153.
49. Kripalani, K.J., Cohen, A.I., Weliky, I. and Schreiber, E.C. (1975) Metabolism of triamcinolone acetonide-21-phosphate in dogs, monkeys and rats. J. Pharm. Sci. 64, 1351-1359.
50. Loo, J.C.K., McGilveray, I.J., Jordan, N. and Brien, R. (1981) Pharmacokinetic evaluation of betamethasone and its water-soluble phosphate ester in humans. Biopharm. Drug Dispos. 2, 265-272.
51. Bailey, E., Murphy, D. and West, H.F. (1962) Oral prednisolone phosphate therapy. Arch. Dis. Child. 37, 71-74.